Rong Zhang

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Rong Zhang sits in the upper half of US sponsors by registered trial count (#7,388 of 15,742 sponsors by registered trial count).

1 total trials 1 currently recruiting early-phase tilt upper half by trial count

Rong Zhang: 1 sponsored US clinical trial, 1 recruiting.

Rong Zhang sponsors 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Family History of Dementia, with 1 trials.

Mid-pack sponsor footprint

Rong Zhang is in the upper half of sponsors by trial count (#7,388 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

Open and recent trials

1 total, page 1 of 1

RECRUITING Phase 2

Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)

NCT05331144

Phase Distribution

PhaseTrial count
Phase 2 1

Therapeutic Areas

Family History of Dementia 1
Cognitively Normal Older Adults 1
Subjective Cognitive Decline 1
Hypertension 1

What is open in the Rong Zhang pipeline

1 recruiting of 1 indexed (100% open).

Phase mix: 0 late (III/IV) vs 1 early (I/II) (early-phase heavy).

Top condition: Family History of Dementia (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Rong Zhang: open-pipeline peers nationwide

Peers matched on 1 registered trials and 100% open enrollment, not the therapeutic-area sidebar.

Rong Zhang sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 012345 0%50%100%150% Total trials Recruiting share Rong Zhang1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO HealthAAVantgarde Bio SrlAcorn BiolabsAcrivon TherapeuticsADARx Pharmaceuticals
Rong Zhang sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rong Zhang sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1 trials (± recruiting share)

Sponsors near 100% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rong Zhang page

1 registered trials is a research-attention snapshot, not an endorsement of Rong Zhang or any single study.

  • 1 of Rong Zhang's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Family History of Dementia is the condition Rong Zhang studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Family History of Dementia trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rong Zhang pipeline card: 1 registered trials from official public datasets.Report a data error.